

# Incidences

- More than of 70% of healthy women have vaginal Candidiasis.
- The most common affected area

Gastrointestinal tract (mainly mouth cavity)

Vaginal mucosa

Skin.

Predisposing factors:


Immunocompromised states (disease & stress),

Old age


Antibiotic treatment


### In-vitro adhesion inhibition assay


- 1. Prepare monolayer of FaDu cells in 24-well plate
- 2. Mix Specific IgY (CA) with Candidia albicans (5x10<sup>6</sup> CFU/ml)
- 3. Incubate at 37 C for one hr
- 4. Add 500µl of the mixture to cells
- 5. Incubate at 37 C for one hr
- 6. Wash with PBS
- 7. Count the CFU in YPD agar




PBS-treated









MP:X200

# Inhibition of Candidia albicans adherence by Specific IgY (CA)

Trial	st	2 <sup>nd</sup>	3 <sup>rd</sup>	<b>4</b> <sup>th</sup>	5 <sup>th</sup>
Challenge dose	I ×10 <sup>3</sup>	$7 \times 10^3$	7 × 10 <sup>6</sup>	$3.4 \times 10^6$	5 x 10 <sup>6</sup>
Specific IgY (CA) *	1.46	1.1	3.3	2.9	2.3
PBS treated*	2.48	2.8	6.2	5.8	5.9
Inhibition ratio	90.33	97.3	99.90	99.87	99.98

<sup>\*</sup> Log 10 of adhered CFU/ml

# Pilot study

#### Protocol of the study

Number of volunteer: Two

Length of treatment: 3 month (3 steps)

1.First step: Treatment with 500 mg/day for one month (5 tablets a day).


One tablet contains 100 mg of Specific IgY (CA).

- 2. Second step: Stop of treatment for one month
- 3. Third step: Treatment with 250 mg/day for one month (5 tablets a day).

  One tablet contains 50 mg of Specific IgY (CA).

Sample: Saliva sample

Candida count: Count on Candida GE agar and Candida ID agar



# **Pilot trial result**

